Stocks · News reference
Filed: 2026-10-14 AccNo: 0001193125-26-421076 Size: 174 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success